# Amlodipine as add-on to Olmesartan in Hypertension

> **NCT00220220** · PHASE3 · COMPLETED · sponsor: **Sankyo Pharma Gmbh** · enrollment: 429 (estimated)

## Conditions studied

- Essential Hypertension

## Interventions

- **DRUG:** olmesartan medoxomil
- **DRUG:** amlodipine

## Key facts

- **NCT ID:** NCT00220220
- **Lead sponsor:** Sankyo Pharma Gmbh
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-04
- **Primary completion:** —
- **Final completion:** 2007-04
- **Target enrollment:** 429 (ESTIMATED)
- **Last updated:** 2018-12-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00220220

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00220220, "Amlodipine as add-on to Olmesartan in Hypertension". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT00220220. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*